CDKN3 overexpression can shorten the survival of HCC cells and shift sensitivity to chemotherapeutic drugs across the AKT/P53/P21 signaling pathway; besides, CDKN3 has been shown to be downregulated in advanced tumor stages (Dai et al., 2016). Here, TP53 is linked to neoplasm.